Next Article in Journal
Is there A Role for Alpha-Linolenic Acid in the Fetal Programming of Health?
Next Article in Special Issue
MicroRNAs in the Evaluation and Potential Treatment of Liver Diseases
Previous Article in Journal
New Insights into the Crossroads between EMT and Stemness in the Context of Cancer
Previous Article in Special Issue
Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2016, 5(3), 38; doi:10.3390/jcm5030038

Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis

1
Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
2
21st Century Oncology, 4571 Colonial Blvd., Suite 210, Fort Myers, FL 33966, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Rajagopal N. Aravalli
Received: 20 November 2015 / Revised: 23 February 2016 / Accepted: 7 March 2016 / Published: 16 March 2016
(This article belongs to the Special Issue MicroRNAs: Novel Biomarkers for Liver Diseases)
View Full-Text   |   Download PDF [711 KB, uploaded 16 March 2016]   |  

Abstract

microRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by either blocking translation or inducing degradation of target mRNA. miRNAs play essential roles in diverse biological and pathological processes, including development of hepatic fibrosis. Hepatic stellate cells (HSCs) play a central role in development of hepatic fibrosis and there are intricate regulatory effects of miRNAs on their activation, proliferation, collagen production, migration, and apoptosis. There are multiple differentially expressed miRNAs in activated HSCs, and in this review we aim to summarize current data on miRNAs that participate in the development of hepatic fibrosis. Based on this review, miRNAs may serve as biomarkers for diagnosis of liver disease, as well as markers of disease progression. Most importantly, dysregulated miRNAs may potentially be targeted by novel therapies to treat and reverse progression of hepatic fibrosis. View Full-Text
Keywords: liver disease; microRNA; hepatic stellate cell; liver fibrosis liver disease; microRNA; hepatic stellate cell; liver fibrosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kitano, M.; Bloomston, P.M. Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis. J. Clin. Med. 2016, 5, 38.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top